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Objectives This was a 2-year follow-up study of a 
primary care-based counselling intervention (weave) for 
women experiencing intimate partner violence (IPV). We 
aimed to assess whether differences in depression found 
at 12 months (lower depression for intervention than 
control participants) would be sustained at 24 months and 
differences in quality in life, general mental and physical 
health and IPV would emerge. 
Design Cluster randomised controlled trial. Researchers 
blinded to allocation. Unit of randomisation: family doctors. 
Setting Fifty-two primary care clinics, Victoria, Australia. 
Participants Baseline: 272 English-speaking, female 
patients (intervention n=137, doctors=35; control n=135,
doctors=37), who screened positive for fear of partner 
in past 12 months. Twenty-four-month response rates:
intervention 59% (81/137), control 63% (85/135). 
Interventions Intervention doctors received training to 
deliver brief, woman-centred counselling. Intervention 
patients were invited to receive this counselling (uptake 
rate: 49%). Control doctors received standard IPV 
information; delivered usual care. 
Primary and secondary outcome measures Twenty-
four months primary outcomes: WHO Quality of Life-Bref 
dimensions, Short-Form Health Survey (SF-12) mental 
health. Secondary outcomes: SF-12 physical health and 
caseness for depression and anxiety (Hospital Anxiety 
Depression Scale), post-traumatic stress disorder (Check 
List-Civilian), IPV (Composite Abuse Scale), physical 
symptoms (≥6 in last month). Data collected through postal 
survey. Mixed-effects regressions adjusted for location 
(rural/urban) and clustering. 
Results No differences detected between groups 
on quality of life (physical: 1.5, 95% CI −2.9 to 5.9; 
psychological: −0.2, 95% CI −4.8 to 4.4,; social: −1.4,
95% CI −8.2 to 5.4; environmental: −0.8, 95% CI −4.0 to 
2.5), mental health status (−1.6, 95% CI −5.3 to 2.1) or 
secondary outcomes. Both groups improved on primary 
outcomes, IPV, anxiety. 
Strengths and limitations of this study 
► Well-designed cluster randomised controlled trial of 
primary care intervention for women experiencing 
intimate partner violence (IPV), addressing a major 
gap in existing evidence to guide practice. 
► Long-term follow-up, rarely reported in this popula-
tion, tested whether outcomes from an IPV interven-
tion were sustained at 2 years or emerged over this 
extended time period. 
► Two-year retention rates (~60%) were similar 
across groups and acceptable for the population 
under study; low rate of active withdrawal (18%); 
and no reporting of adverse events, indicate no harm 
from either the intervention or study participation. 
► A low counselling intervention dose was delivered 
overall, with 49% of intervention group women tak-
ing up the invitation to attend counselling sessions,
and the majority only attending only one session. 
► Socially disadvantaged women, younger women 
and women of non-English speaking background 
were under-represented in the sample limiting gen-
eralisability for these populations. 
Conclusions Intervention was no more effective than 
usual care in improving 2-year quality of life, mental and 
physical health and IPV, despite differences in depression 
at 12 months. Future refnement and testing of type,
duration and intensity of primary care IPV interventions is 
needed. 
Trial registration number ACTRN12608000032358. 
INTRODUCTION 
Intimate partner violence (IPV) is a common 
issue among women attending primary 
healthcare services, and a leading cause 
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childbearing age.1 2 Research suggests that around 13% of 
women attending a family doctor in Australia have expe-
rienced fear of their partner or ex-partner in the past 12 
months,3 and 30% at some point in their lives.4 Similarly, a 
study of female patients attending general practice in the 
UK found that 17% had experienced physical violence 
from a partner or ex-partner in the past 12 months.5 IPV 
is often associated with physical and psychological health 
damage, including depression, anxiety, chronic pain, 
gynaecological and general health issues.1 6 7 In such situ-
ations, the presenting condition may be unresponsive 
to treatment unless the impact of IPV is also addressed. 
Furthermore, family doctors may be the first or only point 
of contact for many women experiencing IPV, and hence 
are in a unique position to assist.8 It is, therefore, imper-
ative that family doctors are equipped to identify and 
respond to IPV.9–11 
Despite the important role family doctors have to play 
in identifying and responding to IPV, there have been 
limited trials in primary care settings to guide effective 
interventions.8 12 Reviews of IPV interventions found that 
most primary care-based trials have been in reproductive 
health or pregnancy contexts, rather than broader family 
practice settings, and none of the studies tested doctor-
delivered interventions.12 13 Another recent systematic 
review in 2017 also revealed limited evidence to base 
guidance for general practitioners and family doctors.14 
Hence, WHO and others have called for more evidence 
on interventions following identification of IPV.8 11 12 
In response to this need for IPV intervention trials in 
primary care settings, Hegarty et al undertook the weave 
trial.15 16 Fifty-two family doctors/clinics were recruited, 
along with 272 of their female patients who had expe-
rienced fear of a partner or ex-partner in the past 12 
months. Family doctors assigned to intervention were 
trained to deliver woman-centred counselling by offering 
up to six, 30 min sessions using motivational interviewing 
or non-directive problem-solving techniques depending 
on the patient’s readiness to change.16 17 The control 
group received usual care. At 6-month follow-up, more 
women in the intervention group than the control group 
had been asked by their doctor about their safety and that 
of their children. At 12-month follow-up, rates of depres-
sion were lower for the intervention group than the 
control group. However, there were no significant differ-
ences at either time point on quality of life or general 
mental health status or safety planning, which were 
primary outcomes. Only half of the intervention group 
took up the invitation to attend the counselling sessions, 
and many of these women only attended one session.15 18 
This paper reports results of the 24-month follow-up of 
the weave trial. First, we were interested in whether group 
differences in quality of life and general mental health 
would emerge by 24 months post baseline. Quality of life is 
a complex, multifaceted construct which may take time to 
develop,19 and it is possible the initial 12-month follow-up 
period was insufficient for improvements to be detected 
in the intervention group. Similarly, it is plausible that 
it may take longer for overall mental health status to 
show an effect. Any small improvements the intervention 
group had made on these primary outcomes by 12-month 
follow-up had been matched by improvements in the 
control group. This could have been due to common 
aspects of study involvement, such as survey completion 
and reminder calls, prompting positive changes for both 
groups, or due to both groups accessing other support 
services outside of primary care.15 20 The 24-month 
follow-up allowed us to test whether this pattern would 
continue once contact with participants was less frequent. 
Second, we were interested in whether rates of depres-
sion would remain lower for the intervention group than 
control group at the 24-month time point. This would 
help assess whether the impact of family doctor-delivered 
counselling on depression could persist over an extended 
time, once the counselling intervention has ceased. Third, 
we were interested in whether levels of IPV, post-traumatic 
stress disorder (PTSD) and physical symptoms would be 
lower for the intervention group than the control group 
by 24 months. Based on prior theory and research,21 22 it 
was anticipated that any external reduction in IPV would 
take longer to emerge and improve PTSD symptoms than 
internal changes such as reduced depression.16 
Specifically, we investigated whether, at 24 months after 
the counselling invitation, there was a difference between 
intervention and control groups (on the individual partic-
ipant level) for: 
► Quality of life dimensions (physical, psychological, 
social, environmental) and general mental health 
status (primary outcomes). 
► Physical health status and caseness for IPV, depres-
sion, anxiety, PTSD and physical symptoms (secondary 
outcomes). 
We also explored within-groups effects, to determine if 
groups had changed on these outcomes from baseline to 
24 months. 
METHODS 
Study design and participants 
Our protocol, trial methods, baseline characteristics, 
intervention and 6-month and 12-month response rates 
and outcomes are published elsewhere.3 15 16 23 24 Briefly, 
we undertook a cluster randomised controlled trial with 
family doctors and their female patients who had been 
fearful of a partner or ex-partner in the past 12 months. 
The trial reporting conformed to Consolidated Standards 
of Reporting Trials guidelines.25 
As described elsewhere,15 16 family doctors from urban 
and rural practices in Victoria, Australia were recruited 
(one doctor per practice; between 31 January 2008 and 
18 January 2010). All female patients aged 16–50 years 
who had attended that doctor in the past 12 months were 
mailed a brief health and lifestyle screening survey (20 
100 patients from 55 doctors in total).3 Female patients 
were eligible for trial participation if they spoke English, 
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past 12 months and provided contact details. Researchers 
telephoned eligible patients to reconfirm eligibility and 
invite their participation in the trial. Those who agreed to 
participate were mailed a baseline survey to their nomi-
nated safe address, along with an information leaflet and 
resource card. As described in detail elsewhere,15 26 proto-
cols to protect participant safety were followed throughout 
the trial and harm was systematically monitored using an 
adapted version of the Consequences of Screening Tool27 
and a harm–benefit Visual Analogue Scale (0=harmful 
to 100=beneficial). A data monitoring committee moni-
tored the trial’s integrity and reviewed outcome and harm 
data.15 
Randomisation and masking 
Once baseline data had been collected, doctors with 
participating patients were randomised to intervention or 
control groups (between 22 September 2008 and 18 June 
2010).15 Patients were assigned to the same trial group as 
their doctor. Randomisation was by an independent stat-
istician who generated a coded allocation sequence using 
the computer random number generator in Stata V.12.28 
Randomisation was stratified by urban and rural practice 
location with random permuted block sizes of two and 
four within each stratum and an equal allocation ratio for 
two study arms.15 After baseline data had been collected, 
the trial coordinator (not involved in recruitment of 
participants) randomly selected one of the two codes as 
the intervention arm and held the code key in a secure 
location. All other researchers and research personnel, 
including those who recruited doctors and women and 
those who undertook analyses, were blinded to study arm 
allocation until results had been interpreted and prelim-
inary write-up undertaken. The trial coordinator was 
responsible for notifying doctors of their assigned study 
arm. It was not possible to mask doctors and patients after 
randomisation, as doctors needed to receive training and 
women were offered counselling. 
Intervention 
As described in detail in previous publications,15 16 23 the 
study intervention consisted of training doctors, noti-
fying doctors of women who screened positive for fear 
of a partner, and inviting women for brief counselling 
with their doctor for relationship and emotional issues. 
The intervention was based on the psychosocial readiness 
model, which describes both internal and external factors 
in the process of change for IPV survivors.21 23 Internal 
factors in the psychosocial readiness model include aware-
ness that the perpetrator’s behaviour is abuse, perceived 
support from others and self-efficacy or perceived power.21 
The doctor training was delivered as a Healthy Relation-
ships Training programme, consisting of a 6-hour distance 
learning package, and a 1-hour interactive practice visit 
delivered by a clinician academic.23 The training aimed 
to equip doctors to respond to women experiencing IPV 
and to deliver a brief counselling intervention. It used 
a patient-centred care approach, emphasising active 
listening, motivational interviewing, problem-solving 
techniques, validating women’s experiences and feelings, 
assessing readiness for change, and supporting decisions. 
Following this training, patients in the intervention group 
were mailed a letter from their weave doctor, inviting 
them to attend counselling sessions. Patients could attend 
between one and six counselling sessions, over a 6-month 
period, at no cost to the patient. Just under half of the 
intervention group attended counselling (49%, n=67), 
with most only taking up one session.15 18 In both inter-
vention and control groups, doctors received a basic IPV 
information pack and ontinuing professional develop-
ment points and patients received a list of resources with 
each survey. Women in the control group received stan-
dard care from their doctor if they attended during the 
study period. 
Data collection 
Trial outcomes were measured at the individual level, 
at baseline, 6 months, 12 months and 24 months, using 
postal surveys sent to each participating woman’s nomi-
nated safe address. The current study focuses on 24-month 
outcomes of the trial, collected from 15 March 2011 to 
1 November 2012. Primary outcomes measured at 24 
months were quality of life dimensions (physical, psycho-
logical, social and environmental on the WHO Quality 
of Life Brief Version)29 and Short Form Health Survey 
(SF-12) mental health status.30 Secondary outcomes were 
IPV caseness (score ≥7 on the Composite Abuse Scale),31 
depression and anxiety caseness (score ≥8 on the Hospital 
Anxiety Depression Scale),32 PTSD caseness (score ≥50 
on the PTSD Check List-Civilian version; this cut-off score 
has shown sound sensitivity and specificity in previous 
studies)33 34; physical symptoms caseness (sum ≥6 in last 
month) and SF-12 physical health status.30 
Statistical analyses 
We calculated that a minimum sample size of 136 women 
from 34 doctors (four women per doctor) would be 
needed to detect the prespecified effect size of half an SD 
difference on primary outcomes, with 80% power (α=5%, 
two-sided test).15 This was based on a two-sample t-test, 
allowing for a design effect of 1.08, due to clustering.35 
Further details on sample size calculations for initial 
screening and recruitment phases are published else-
where.15 16 It was anticipated that around 60% out of the 
272 trial participants would return their 24-month survey, 
and thus the required sample size would be exceeded. 
Analyses were performed in Stata V.12,28 using mixed 
effects linear regression for continuous outcomes and 
mixed effects logistic regression for binary outcomes, 
with robust standard errors.36 Study group was fitted as 
a fixed effect and change over time from baseline as a 
random effect. Analyses adjusted for location (rural 
vs urban) and clustering of data by practice and were 
conducted according to intention-to-treat principles. All 
available data were included from all participants who 
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completed all follow-up time points, and for interven-
tion group participants, regardless of whether they had 
attended the counselling intervention. In order to assess 
whether uptake of the intervention affected 24-month 
findings, supplementary subgroup analyses were 
performed which excluded intervention group partici-
pants who had not attended the counselling intervention. 
Patient and public involvement 
The weave study was designed with input from a reference 
group consisting of community organisation representa-
tives and medical professionals, including a family doctor. 
The data monitoring committee also included a repre-
sentative from a community organisation that provides 
IPV-related services and information. 
FINDINGS 
Baseline characteristics of doctors and women enrolled in 
the weave trial are described in detail elsewhere (see also 
online supplemental table 1).15 These characteristics were 
even across intervention and control groups.15 Mean age 
of family doctors was 48.1 years (SD=8.1), which is similar 
to the mean age overall for family doctors in Australia 
(49.3 years).15 Sixty-two per cent (n=32) of family doctors 
in the trial were female, compared with 39% overall of 
Australian family doctors.15 Nonetheless, their commu-
nication skill levels were similar to other family doctors 
and few had prior training in IPV.15 Seventy-one per 
cent (n=37) of doctors in the trial were from urban prac-
tices. Mean baseline age of patients in the trial was 38.5 
(SD=8.1), with 16% (n=44) aged 17–29, 31% (n=83) 
aged 30–39 and 53% (n=140) aged 40–50. Fifty-three per 
cent (n=144) lived with a partner at baseline and 59% 
(n=159) had children under 18 years old at home. Year 
12 schooling had not been completed by 42% (n=114) 
of participants, 30% (n=73) were not currently employed 
and 23% (n=61) received a government pension as their 
main source of income. The majority of participants 
(94%, n=257) spoke English as their first language. 
Figure 1 shows the flow of participants through the 
trial. The 24-month response rate was 59% (81/137) in 
the intervention group and 63% (85/135) in the control 
group. The number of participants retained and anal-
ysed at this time point exceeded the sample size needed 
to detect prespecified differences on outcome variables. 
Baseline characteristics were similar for participants who 
did and did not return the 24-month survey (online 
supplemental table 1). There were also no statistically 
significant differences between those who did and did 
not return the 24-month survey on previous time point 
measures of quality of life, SF-12 mental or physical 
health status, depression, anxiety or IPV caseness (see 
online supplemental table 2; PTSD and physical symptom 
caseness was not assessed at previous time points). There 
were also no statistically significant differences between 
intervention and control groups on use of health services 
or other professional support services at any time point 
(see online supplemental table 3–8). 
We detected no differences between intervention and 
control groups on quality of life dimensions or SF-12 
mental health status at 24 months (table 1). Both inter-
vention and control groups improved on quality of life 
dimensions and SF-12 mental health status from base-
line to 24 months (table 1), although examination of 
12-month data shows that most of this improvement had 
occurred during the 12 month time frame (12-month data 
are reported elsewhere; see also means and SDs reported 
in online supplemental table 2).15 We also detected no 
differences between groups at 24 months on caseness for 
IPV, depression, anxiety, PTSD or physical symptoms, nor 
on SF-12 physical health status (table 2). Both interven-
tion and control groups displayed lower IPV and anxiety 
caseness at 24 months than at baseline (table 2). For IPV 
caseness, most of this improvement had occurred during 
the 12-month time frame.15 There were also no differences 
between groups on 24-month outcomes when excluding 
intervention group participants who had not attended 
the counselling intervention (online supplemental tables 
9 and 10). When excluding these non-attenders the same 
patterns of improvement from baseline to 24 months on 
IPV, anxiety and primary outcomes were found (online 
supplemental tables 9 and 10). Supplementary analyses 
of fear levels (in the last 2 weeks and 6 months ago) also 
found no significant differences between groups at 24 
months, regardless of whether or not analyses excluded 
intervention non-attenders (online supplemental tables 
11 and 12). 
As detailed in a previous publication,26 there were no 
significant harms detected. Most 24-month survey respon-
dents agreed that they were glad they participated in 
the project (n=145, 87.3%). We detected no differences 
between groups on the harm–benefit Visual Analogue 
Scale used as part of harm assessment (intervention 
mean=77.0 (SD 20.5); control mean=73.7 (SD 18.9); 
mean difference=4.4, 95% CI −0.8 to 9.6, p=0.092). 
DISCUSSION 
The current analyses reported on findings from the 
weave trial at 24-month follow-up. As had been found at 
12-month follow-up,15 there were no significant differ-
ences between intervention and control groups on the 
primary outcomes of quality of life or overall mental health 
status. For both groups, quality of life and mental health 
status remained stable from 12 months to 24 months, 
having improved in both groups between baseline and 12 
months.15 There were no significant differences between 
groups on depression caseness at 24 months, despite this 
difference being present at 12 months. There were also 
no differences between groups on physical health status 
or symptoms, nor on caseness for anxiety, PTSD or IPV at 
24 months. Instead, by 24-month follow-up both groups 
showed lower rates of anxiety and IPV than they had at 
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 Figure 1 Weave trial Consolidated Standards of Reporting Trials fow diagram. aReasons for ineligibility: afraid more than 12 
months ago (50); no longer visits the weave doctor (5); misinterpreted the fear item (34); poor English (1); outside age range 
(1). bExcluded from complete case analysis but retained in trial. cAnalyses and fndings are reported in the weave 6–12 months 
outcome paper. dReasons for withdrawal: does not wish to give reason (4), no longer interested/not relevant (4), too busy/ 
survey too long (3), weave doctor not their usual family doctor (2), wants to move on (1); eDoes not wish to give reason (2), no 
longer interested/not relevant (1), too busy/survey too long (1), wants to move on (1); fDoes not wish to give reason (1), no longer 
interested/not relevant (1), unhappy with weave doctor (1); gDoes not wish to give reason (1), no longer interested/not relevant 
(1); hDoes not wish to give reason (1), no longer interested/not relevant (7), too busy/survey too long (1), wants to move on (2); 
iDoes not wish to give reason (2), no longer interested/not relevant (9), too similar to 12 months survey (1), wants to move on (1), 
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poor mental health, physical health and IPV remained at 
concerning levels. 
Strengths and limitations of the weave trial have been
discussed in detail elsewhere.15 18 26 To the authors’
knowledge, this study remains the only trial to date
of an IPV intervention delivered directly by family
doctors to their female patients in primary care.13 
Other strengths included low risk of bias arising from
the randomisation process; using doctors (and their
practice) as the unit of randomisation, to minimise risk
of contamination; low rate of active withdrawals; and
no differences between the arms in terms of missing
data or drop-outs. The management of safety was also
a strength, for example, our systematic monitoring of
participant safety. Retention rates met prespecified
requirements, and were high for this field of research,
with multiple retention strategies in place including
follow-up contact, participant newsletters, and allowing
participants to nominate multiple safe addresses and
preferred contact times. Outcome assessment was by
self-report; notwithstanding this, few IPV trials have
included 24-month follow-up, and none that involve
family doctor interventions.13 One constraint of the
weave trial, common to the delivery of trials across the
field, was that masking of doctors and patients was not
possible, due to the nature of the trial.15 Also, sample
characteristics may restrict generalisability of findings
to other similar populations and settings. Patients who
returned the initial screening survey were more likely
to be employed, born in Australia and have completed
secondary schooling than the Australian female popu-
lation; further, women not fluent in English were
excluded from the sample.3 Young women (ie, between
16 and 29 years of age) were under-represented in the
sample. Also, the rate of female family doctors was
higher for the weave trial than for Australian family
doctors in general, although their communication skill
levels were similar to other family doctors and few had
prior training in IPV.15 
One key challenge in the weave trial was the low uptake 
of the brief counselling intervention, and the limited 
number of sessions attended by those who did take up 
this offer.15 18 Similar challenges with engaging women in 
an intervention have also been experienced in previous 
trials.37 Interview data as part of a weave process evaluation 
identified several barriers that prevented some women 
attending services when offered.18 These included the 
belief that family doctors only treat physical problems, 
perceptions around time pressures that family doctors 
face, and fears about managing emotional aspects of the 
session (eg, fear of breaking down in tears or not knowing 
where to start). Poor emotional health or embarrassment 
about emotional health status also made it difficult for 
some women to attend appointments. Quantitative anal-
yses showed that those who did not attend the counselling 
intervention were more likely to be in a current relation-
ship and rated their weave doctor’s communication skills 
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may need to focus further on addressing these potential 
barriers. 
With regard to depression, the current findings suggest 
that family doctor-delivered, brief counselling for IPV is 
only more effective than usual care within a year of being 
implemented. In the longer term, after cessation of coun-
selling, differences between groups on depression are not 
maintained. Further research is needed to test whether 
the difference between intervention and control groups 
on depression found at 12 months could persist in the 
longer term if counselling was better attended or offered 
at additional time points, for example, in year 2. The 
current findings also suggest that brief counselling is no 
more effective than usual care in improving quality of 
life, general mental or physical health, anxiety, PTSD and 
abuse levels for IPV survivors at 24 months. Again, the 
low uptake of counselling may have contributed to these 
null findings, or, alternatively these complex outcomes 
may require more multifaceted, long-term interventions. 
It may be that the study did not take sufficient account of 
the extent to which survivors need different interventions 
at different points in their journey, which extend beyond 
the theoretical approaches adopted in the current model 
of weave. For example, there will be considerable vari-
ation across IPV survivors within a primary care sample 
in terms of psychological, safety, advocacy and children’s 
needs depending on whether violence is ongoing; the 
nature, frequency and severity of the violence; the pres-
ence of trauma symptoms; past exposure to abuse; and 
available support networks. 
Another important consideration is that by the
24-month time point, both groups had improved on all
outcomes except depression and SF-12 physical health
status (PTSD and number of physical health symptoms
were not measured at baseline). As outlined earlier, it
is possible that initial improvements could have been
due to study-related influences experienced by both
groups, such as survey completion and participant
reminders.15 20 If so, this could have attenuated the
intervention effect. Despite these improvements, the
burden of disease remained high at this 2 years time
point. Many of the women still experienced IPV by a
partner or ex-partner and had significant mental and
physical health issues. This points to the need for long-
term, multifaceted system responses to the complex
issues surrounding IPV.38 
Future studies are needed to refine the intervention 
further and assess whether and what aspects of this 
refinement enable long-term effects. Key areas to target 
include uptake, duration and intensity of the interven-
tion, including conceptual development of interventions 
for survivors with a diverse range of experiences and an 
assessment of patient’s readiness and ability to take up 
the intervention. With regard to uptake, barriers and 
facilitators identified as part of the weave process evalu-
ation could be used as a guide for increasing uptake in 
future studies.18 Some women’s concerns about attending 
primary care may be alleviated through messaging that 
family doctors are open and trained to address emotional 
and social issues, improving the communication skills of 
doctors and providing more time through continuity of 
care. Duration of the intervention could be increased, for 
example by inviting participants for periodic follow-up 
or ‘booster’ counselling sessions after the initial round 
of counselling sessions. Training of doctors could further 
emphasise strategies to continue ongoing support and 
monitoring of patient progress, beyond the initial inter-
vention phase. Further IPV trials with greater diversity 
including more young women, different cultural back-
grounds, Indigenous peoples, and diverse gender and 
sexual identities are also needed. 
In conclusion, this 24-month follow-up analyses of the 
weave trial found that training family doctors to deliver a 
brief counselling intervention, and inviting their female 
IPV survivors to attend this counselling, was no more 
effective than usual care in improving long-term quality 
of life, mental and physical health and IPV exposure. 
This is despite shorter-term effects of the intervention 
on depression (at 12 months) and doctor enquiry about 
safety (at 6 months).15 Further research is needed to test 
whether refining the uptake, duration and intensity of the 
intervention could have an effect on long-term outcomes. 
We urgently need to test additional healthcare interven-
tions for IPV, including system responses38 to enable 
healing and pathways to safety for women exposed to IPV 
attending primary care settings.39 
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